Stifel upgraded Danaher (DHR) to Buy from Hold with a $260 price target Light Up your Portfolio with Spark:Easily identify stocks' risks and ...

As previously reported, Stifel analyst Daniel Arias upgraded Danaher (DHR) to Buy from Hold with an unchanged price target of $260, telling ...

Persistent softness in the Life Sciences segment weighs on DHR's performance. An increase in operating expenses is an added ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” fourth quarter 2024 investor letter ...

Shareholders of Danaher would probably like to forget the past six months even happened. The stock dropped 23.9% and now ...

AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...

With a market cap of $148.5 billion, Washington, the District Of Columbia-based Danaher Corporation (DHR) is a global ...

AbbVie, Danaher, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock ...

Shares of Danaher Corp. DHR slid 1.28% to $212.07 Friday, on what proved to be an all-around positive trading session for the ...

Danaher Corporation (NYSE:DHR), a global science and technology innovator with a market capitalization of $146 billion, has been navigating a complex landscape of opportunities and challenges in ...

Shares of Danaher Corp. DHR slipped 3.23% to $205.23 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.70% to 5,614.56 and Dow ...